FDA provides fast track designation to nipocalimab for systemic lupus erythematosus
Medical Xpress - medical research advances and health news [Uno…
March 12, 2026
Johnson & Johnson's nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE).
Discussion in the ATmosphere